BRCA1 and cancer: Furthermore our study depicted an improved OS in patients non-BRCAmut HRD supporting the hypothesis that non-BRCAmut HRD and possibly BRCA1 promotor methylated EOCs are an important subset of cancers with impaired HRR [10,14].